Fig. 5.

CYP-inhibition enhances the nephrotoxicity of OTA. A H&E staining; scale bars 50 µm. B CD45 immunostaining; scale bars 10 µm. C Serum creatinine and blood urea nitrogen. D NGAL and KIM-1 urinary concentrations 24 h after OTA administration with and without ABT compared to vehicle or ABT controls; **p value ≤ 0.01 Tukey’s multiple comparisons test; n = 5 mice per group. The same experimental design as in Fig. 3 was applied